arrow
S

Sham Mailankody

Memorial Sloan Kettering Cancer Center
H指数:47
被引数:8,540

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma

基于病灶水平的PET/CT分析以识别多发性骨髓瘤中BCMA CAR T细胞治疗后进展的预测因子

2026-08-190
OAAI
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

粒细胞集落刺激因子对双特异性抗体启动期间细胞因子释放综合征的影响:在复发/难治性多发性骨髓瘤中的作用

2026-08-070
OAAI
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

在多发性骨髓瘤患者中,强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关(cilta-cel治疗)

2026-07-290
PRE
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

功能性高风险疾病与多发性骨髓瘤晚期CAR T细胞疗法后的不良预后相关

2026-04-120
OAAI
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

双特异性抗体治疗复发/难治性多发性骨髓瘤期间巨细胞病毒再激活

2025-11-010
OAAI
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

更正:达鲁珠单抗耐药性对复发难治性多发性骨髓瘤接受CAR T细胞治疗后临床结局的影响

2025-10-130
OA
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

daratumumab难治性对复发性难治性多发性骨髓瘤CAR T细胞治疗后临床结局的影响

2025-08-140
OAAI
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Barriers to Chimeric Antigen Receptor T-Cell Therapy

嵌合抗原受体T细胞疗法中的障碍

2025-05-150
PRE
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

老年体弱患者接受BCMA靶向双特异性抗体治疗复发/难治性多发性骨髓瘤的结局

2025-05-060
OA
Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

在长期剂量延迟后重新开始teclistamab和talquetamab治疗,可能不需要重新进行剂量递增。

2025-03-100
OA
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma

CC-98633/BMS-986354(B细胞成熟抗原[BCMA] NEX-T®嵌合抗原受体[CAR] T细胞疗法)在经三药类治疗暴露的多发性骨髓瘤患者中的I期临床试验

LEUKEMIA
IF13.4
2025-02-051
OA